Biotech, in brief

The FDA, the US drug regulator, approved Voceryq on Friday for a rare airway disease. [1]

The disease, recurrent respiratory papillomatosis, grows wart-like lumps in the airways. [1]

A virus causes the growths: HPV, types 6 and 11. [1]

The drug company Inovio Pharmaceuticals makes Voceryq and won the approval. [1]

It is the first US approval for an immune treatment built from plasmid DNA. [1]

Patients may face fewer throat operations, the FDA says. [1]

Regulators call this accelerated approval: a yes given on an early sign of benefit. [1]

Here the early sign is fewer operations, which the FDA judges likely to mean real benefit. [1]

The trial counted operations only in the first year, so longer effects are unknown. [1]

Inovio must now run more trials to confirm the benefit. [1]

The FDA approved Inovio's Voceryq because fewer patients needed throat operations in the first year of an open trial of 32 adults, and Inovio must still prove the benefit in more trials. [1]

It can sell Voceryq now on an accelerated approval, before the confirming trials finish. [1]

They get a new option beside repeated surgery, built to make the immune system attack infected cells. [1]

How long Voceryq's effect lasts.

The trial counted operations only in the first year after treatment, and the trials that must confirm the benefit have not reported. [1]

How Voceryq compares with surgery alone.

The FDA describes the trial as open-label and gives results for treated patients only, with no comparison group named. [1]

Seven of 26 adults with a rare airway disease, who had each needed three or more operations, needed none for a year after Voceryq, which the US approved on Friday.

Gilead Sciences, a big drugmaker, paused two trials of its cell treatment KITE-753. [2]

KITE-753 is a CAR-T: a patient's own immune cells, rebuilt to attack cancer. [2]

It is meant for diffuse large B-cell lymphoma, a cancer of white blood cells. [2]

Gilead told investors on 29 October that it agreed a partial hold with the FDA. [2]

The paused trials are PALISADES-1, a mid-stage test, and PALISADES-2, a final-stage one. [2]

A small number of patients had grade 3 or 4 ICANS, a serious brain side effect. [2]

ICANS can bring fever, confusion and tremors. [2]

Gilead's cell-treatment chief, Cindy Perettie, said no patient died. [2]

In an early trial last year, KITE-753 was tested with a sister treatment, KITE-363. [2]

Cancer could no longer be found in 71% of those patients. [2]

The pause hits Gilead's cell-treatment arm, whose sales fell 18% to $355 million last quarter. [2]

Drug-safety reviewers pause a trial to check whether a harm comes from the drug or chance. [2]

Gilead has not said how long the review will take. [2]

Why a vaccine can treat an infection the body already has

A virus like HPV gets inside cells and lives there

Antibodies work in blood and body fluids, so they cannot reach it

Infected cells show small pieces of the virus on their surface

Killer T cells that have learned those pieces destroy the infected cells

A treatment like Voceryq teaches T cells the pieces, with IL-12 to boost them

A vaccine given after infection does not block the virus; it teaches the body to find and kill its own infected cells.

Antibodies catch a virus while it is still outside cells. Killer T cells go after cells the virus is already inside.

KITE-753 skips the teaching step: T cells are taken out and rebuilt to find cancer, and that attack caused serious brain side effects in a few patients.

The tumour survives by wearing out the killer T cells that reach it, and blocking ANO6 left more of them able to kill.

Trained T cells do not always win: in Voceryq's trial, 7 of 26 patients needed no operation for a year, so most still needed one.

Most adults carry viruses that hide in their cells, like the one behind cold sores, and T cells keep them in check without anyone noticing.

Gilead paused two trials of its own immune-cell treatment after serious brain side effects in a few patients. [2]

The two trials are on partial hold while Gilead reviews the brain side effects, with no end date given. [2]

What lies behind the brain side effects in KITE-753's later trials.

Gilead says it saw differences in grade 3 and 4 ICANS between phase 1 and phase 2 and is still investigating. [2]

Kenya plans to release 46 people from Ebola quarantine on 3 November. [11]

By then they will have finished the 21 days of checks Kenya requires. [11]

Kenya says it has found no new case in the last 10 days. [11]

Health teams are still following 9 contacts who are now in other countries. [11]

Kenya confirmed its first ever Ebola case on 6 October. [12]

It has had 9 cases and 2 deaths, all linked to that first patient. [11]

Posts online claimed Kenya's health minister, Aden Duale, had announced a lockdown. [12]

Fact-checkers found the claim false: Kenya's health ministry has repeatedly ruled out a lockdown. [12]

The virus reached Kenya from Congo, where confirmed cases have passed 10,000. [12][13]

Epidemiologists call this contact tracing: find everyone exposed, then watch them for symptoms. [11]

Every Kenyan case after the first was already in quarantine when symptoms began. [12]

People leaving quarantine are to get an agreed package of support, the official says. [11]

Whether Kenya's Ebola outbreak is over.

No new case has been found in 10 days, but the last 46 contacts finish monitoring only on 3 November and 9 contacts abroad are still followed. [11]

The Central African Republic has stepped up Ebola checks on its river border with Congo. [13]

At a pier in Bangui, the capital, canoe passengers step off one at a time. [13]

They wash their hands, hear about Ebola and have their temperature checked. [13]

The two countries share a border over 1,500 km long, largely unwatched. [13]

Dr Valentin Nebanga, a Central African health official, says the same communities live on both sides. [13]

Congo's Ebola cases have passed 10,000, and cases have reached Kenya and Nigeria. [13]

Fishers and canoe ferrymen on the Oubangui river earn their living on the water. [13]

Neige, a fishmonger, says river workers "shall be the first to fall victim". [13]

Public health workers call this entry screening: checking for fever where people cross. [13]

Trade on the river carries on despite the risk, the report says. [13]

AstraZeneca, Britain's biggest drugmaker, launched a plan to save $1.5 billion a year. [3]

It will put most of the savings into drugs still in development. [3]

It plans to back more than 180 projects in development. [3]

The plan will cost up to $2 billion in one-off charges. [3]

It is due to be largely complete by the end of 2029. [3]

Sales of Farxiga, its diabetes and heart drug, fell 25% to $1.6 billion. [3]

The fall came after cheaper copies went on sale in the US. [3]

More of its big brands lose patent protection by the mid-2030s, STAT reports. [4]

AstraZeneca aims for $80 billion in yearly sales by 2030, from almost $59 billion in 2025. [3]

Drugmakers call this a patent cliff: sales drop fast once copies are allowed. [3]

Staff may pay for the savings: job cuts are possible, though none are announced. [3]

Most of up to $1.5 billion a year in savings moves into more than 180 projects in development. [3]

Whether AstraZeneca's savings plan means job cuts, and where.

Euronews notes that cuts could follow, but none have been announced, and the plan runs to the end of 2029. [3]

A trial in England and Canada tested a strict diet plus exercise against type 2 diabetes. [5]

In type 2 diabetes blood sugar runs too high; starting young makes it harsher. [5]

The 96 volunteers were aged 18 to 45, had obesity, and did not use insulin. [5]

Fifty followed the diet and exercise plan for 24 weeks; 46 got usual care. [5]

After 24 weeks, 27 of the 50, or 54%, were in remission. [5]

On usual care, 2 of 46, about 4%, were. [5]

Remission means blood sugar stays below the diabetes line without diabetes drugs. [5]

Side effects such as constipation and headaches hit 43 of the 50, mostly early on. [5]

The researchers say longer studies must show whether remission lasts. [5]

Type 2 diabetes is becoming more common among younger adults worldwide, the researchers say. [5]

Doctors call this an open-label trial: the volunteers knew which group they were in. [5]

Remission may not be a permanent cure, and the trial lasted only 24 weeks. [5]

43 of the 50 had at least one side effect, such as constipation, headaches or dizziness. [5]

Whether the diabetes remission lasts outside a trial.

The trial ran for 24 weeks under close supervision, and its authors say longer studies are needed. [5]

In a trial in England and Canada, 27 of 50 young adults with type 2 diabetes were in remission after 24 weeks of diet and exercise, against 2 of 46 on usual care.

Indian regulators ordered Sun Pharmaceutical to stop making eye products at its Assam plant. [4]

The order also stops the company selling and distributing those eye products. [4]

A joint national and state inspection found failures in the plant's quality system. [4]

The order came on 20 August; STAT passed on a Reuters report of it on Friday. [4]

In July, Sun Pharma had itself recalled about 11 eye-care brands. [4]

Sun Pharma had expected the site to become one of its largest sterile-medicine hubs. [4]

Drug plants must run a quality system: rules meant to keep each product safe. [4]

The reports do not say which faults inspectors found or which products were hit. [4]

It cannot make or sell eye products from a plant it expected to be one of its largest sterile-medicine hubs. [4]

What exactly failed at Sun Pharma's Assam plant.

The reports say only that its quality system failed, not which faults or which products. [4]

Novartis, the Swiss drugmaker, will not seek US approval for its heart drug pelacarsen. [14]

In September, pelacarsen failed to protect heart health in a big final-stage trial. [14]

It was meant to lower a particle in the blood called Lp(a). [14]

It was once seen as a possible multibillion-dollar product. [14]

Novartis is not yet sure whether to go on with a second drug aimed at Lp(a). [14]

A week after pelacarsen failed, del-desiran, a muscle-disease drug, failed too. [14]

Novartis faces patent expiry on big drugs and needs new ones, BioPharma Dive reports. [14]

Investors paid first: the two failures pushed Novartis shares down nearly 15%. [14]

David Liu, a gene-editing scientist, spoke this week at ESGCT, Europe's gene and cell therapy meeting. [10]

His idea is fewer treatments that each work for many genetic diseases. [10]

About 30% of genetic diseases have at least one early stop signal in a gene. [10]

That stop signal cuts the protein short, so the body lacks a full working copy. [10]

Liu's team edited a spare tRNA, a helper molecule, to read past that signal. [10]

Humans carry 418 tRNA genes, more than they need. [10]

In mice with Hurler syndrome, an inherited illness, it restored about 7% of enzyme activity. [10]

Liu suggested that much "can rescue the disease". [10]

The Broad Institute and two partners set up a nonprofit to connect rare-disease patients with treatments. [10]

One treatment could then serve many rare diseases that share the same stop signal. [10]

Geneticists call this fault a nonsense mutation: a stop signal in the wrong place. [10]

Liu warned that most genetic diseases are still too rare for companies to pursue. [10]

Scientists at Fox Chase Cancer Center found that a protein, ANO6, helps pancreatic cancer grow. [9]

Pancreatic tumours sit in dense tissue with few working blood vessels. [9]

Support cells around the tumour pass cholesterol to cancer cells, which nibble their surface. [9]

ANO6 is what makes that transfer possible. [9]

The same contact wears out killer T cells, immune cells that destroy cancer. [9]

In mice, two cheap drugs that block ANO6's work, niclosamide and clofazimine, cut tumour weight. [9]

The team published the work in Nature Cancer, a research journal. [9]

This was in mice, and it has not been tested in patients. [9]

The finding could explain part of why pancreatic cancer resists immune treatments. [9]

Cancer biologists call the cells around a tumour its microenvironment, and here it feeds the tumour. [9]

Both drugs also hit other targets, so ANO6 may not explain all of their effect. [9]

The tumour survives by wearing out the killer T cells that reach it, and blocking ANO6 left more of them able to kill.

Whether blocking ANO6 would help people with pancreatic cancer.

The results are in mice, and both drugs used also act on other targets. [9]

Setara Biosciences launched on Friday with $90 million, starting with a drug for a nerve disease. [6]

Its first drug, STAR-0871, targets Charcot-Marie-Tooth disease, which damages nerves in the limbs. [6]

The pill blocks TRPV4, a tiny protein tunnel on cells that runs overactive in patients. [6]

Setara plans a small early trial in patients by the end of the year. [6]

It will also test the pill in overactive bladder. [6]

David Goldstein, who led Actio, now runs Setara. [6]

Jazz Pharmaceuticals bought Actio in August for $1.3 billion, for its epilepsy drug. [6]

Drugmakers have long struggled to change the course of this nerve disease. [6]

Measuring slow nerve damage in a trial is harder than counting seizures, says Goldstein. [6]

Jazz bought Actio's lead drug and also holds a stake in Setara. [6]

Parse Biosciences and Nomic Bio will build Cascade, a dataset of 100 million immune cells. [8]

Parse, owned by QIAGEN, reads which genes are active in single cells. [8]

Nomic measures the proteins that cells release. [8]

Cascade will record how cells react to over 150,000 drug and immune-signal conditions. [8]

GSK, Pfizer and Sanofi, three big drugmakers, have signed up as partners. [8]

Charlie Roco of Parse says biological AI "has hit a data bottleneck". [8]

Biologists call Parse's method single-cell sequencing: reading genes cell by cell, not as a mixture. [8]

Drug companies want such data to build AI models that predict how cells respond. [8]

The data is offered to the drug company partners, the release says. [8]

Opentrons Labworks, which makes lab robots, raised $40 million from investors led by Avego. [7]

It has put more than 11,000 robots in labs in over 80 countries. [7]

The money will go into AI systems that plan, run and learn from experiments. [7]

Its customers include university groups, testing labs and big drug companies. [7]

Earlier this year it began using Nvidia's AI tools to train its robots. [7]

Drugmakers and AI companies are moving lab work onto machines, its lead investor says. [7]

The claim that labs are settling on Opentrons comes from its own chief executive. [7]

Uganda asked the African Union to consider sending its standby force against Ebola. [15]

The African Union, which groups Africa's countries, keeps a force ready for peacekeeping and aid. [15]

Uganda made the call at a meeting of health officials from 45 African countries. [15]

Its health minister said the force could bring medical and supply help, and more staff. [15]

He asked leaders to hold an emergency meeting on paying for it and sending it. [15]

The officials agreed to share information, watch borders more closely and keep them open. [15]

The outbreak has killed nearly 5,000 people in Congo and infected more than 10,000. [15]

It has spread further across Africa than any earlier Ebola outbreak. [15]

Extra staff would ease a shortage of health workers in the response, Uganda says. [15]

Nobody has yet agreed who would pay for the force or when it could go. [15]

Florida's health department held a hearing on dropping 4 school vaccine requirements. [16]

The four are the Hib, chickenpox, pneumococcal and hepatitis B vaccines. [16]

Ending a requirement would not ban a vaccine; families could still choose it. [16]

The author of the analysis is an epidemiologist who studies vaccine-preventable illnesses. [16]

Hib, a bacterium, was once the leading cause of bacterial meningitis, a brain-lining infection. [16]

In the early 1980s, US children under 5 had 20,000 serious Hib infections a year. [16]

After vaccines arrived in the late 1980s, cases in young children fell 99%. [16]

US cases in under-5s rose from 13 in 2023 to 28 so far in 2026. [16]

Fewer vaccinated children puts babies too young for the shots at more risk, the author says. [16]

Epidemiologists call this herd immunity: enough people protected that a disease cannot spread easily. [16]

The risk would reach beyond the families who skip the shots, the author writes. [16]